"i can't think of anything else where we have done that medically," van den veyver said..
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).... however, bentley also warned that these treatments can be hazardous as they may cause bleeding which becomes more likely as the amount of svd increases..